Download Files:
Products Details
Product Description
– L-DOPA-13C6 is the 13C-labled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson’s disease[2][3][4].
Web ID
– HY-N0304S1
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C3 13C6H11NO4
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat Disord. 200814(4):273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease. Front Aging Neurosci. 2018 Aug 310:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154(2):330-5.
CAS Number
– 201417-12-1
Molecular Weight
– 203.14
SMILES
– OC([C@@H](N)C[13C]1=[13CH][13C](O)=[13C]([13CH]=[13CH]1)O)=O
Clinical Information
– No Development Reported
Solubility
– 10 mM in DMSO
Target
– Dopamine Receptor;Endogenous Metabolite
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
